SKP2: Key Regulator of Cell Signaling and Potential Therapeutic Target

Target Name: SKP2

NCBI ID: G6502

SKP2

SKP2: Key Regulator of Cell Signaling and Potential Therapeutic Target

SKP2 (SKP2 variant 3) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a key regulator of cell signaling pathways and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

SKP2 is a member of the SKP2 gene family, which includes four isoforms: SKP2A, SKP2B, SKP2C, and SKP2D. These isoforms differ in their size and/or the presence of certain genetic modifications. SKP2A and SKP2B are predominantly expressed in neural cells, while SKP2C and SKP2D are expressed in other cell types.

SKP2 has been shown to play a crucial role in a number of cellular processes, including cell signaling, cell division, and tissue repair. It is a negative regulator of the TGF-β pathway, which is a well-known regulator of cell signaling pathways that is involved in the development and maintenance of tissues.

SKP2 has also been shown to be involved in the regulation of cell division and cell cycle progression. It has been shown to promote the G1 phase of the cell cycle and to inhibit the S phase. This means that SKP2 helps to control the amount of DNA that is replicated in the cell and the timing of cell division.

SKP2 has also been shown to play a role in the regulation of angiogenesis, which is the process by which new blood vessels are formed. It has been shown to promote the formation of blood vessels in the kidneys and to regulate the growth of blood vessels in the skin.

SKP2 has also been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, SKP2 has been shown to be involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. It has also been shown to be involved in the development of certain autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis.

SKP2 has also been shown to be a potential drug target. Researchers have identified several small molecules that can inhibit the activity of SKP2, and these molecules have been shown to have a variety of potential therapeutic applications. For example, one small molecule, called PF-812552, has been shown to inhibit the activity of SKP2 and to have potential therapeutic applications in neurodegenerative diseases.

Another small molecule, called NX1079, has also been shown to inhibit the activity of SKP2 and to have potential therapeutic applications in cancer. NX1079 is a small molecule that can bind to a protein called ID4, which is a co-factor of SKP2. This means that NX1079 can inhibit the activity of SKP2 and prevent it from regulating the activity of other proteins.

SKP2 is also a potential biomarker for a number of diseases. For example, researchers have shown that SKP2 can be used as a biomarker for the diagnosis of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. They have also shown that SKP2 can be used as a biomarker for the diagnosis of certain autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis.

In conclusion, SKP2 is a protein that is involved in a number of cellular processes and has been implicated in a number of diseases. It is a potential drug target and a potential biomarker for a variety of diseases. Further research is needed to fully understand the role of SKP2 in these processes and to develop effective therapies for the treatment of these diseases.

Protein Name: S-phase Kinase Associated Protein 2

Functions: Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins involved in cell cycle progression, signal transduction and transcription (PubMed:11931757, PubMed:12435635, PubMed:12769844, PubMed:12840033, PubMed:15342634, PubMed:15668399, PubMed:15949444, PubMed:16103164, PubMed:16262255, PubMed:16581786, PubMed:16951159, PubMed:17908926, PubMed:17962192, PubMed:22770219, PubMed:32267835). Specifically recognizes phosphorylated CDKN1B/p27kip and is involved in regulation of G1/S transition (By similarity). Degradation of CDKN1B/p27kip also requires CKS1. Recognizes target proteins ORC1, CDT1, RBL2, KMT2A/MLL1, CDK9, RAG2, FOXO1, UBP43, YTHDF2, and probably MYC, TOB1 and TAL1 (PubMed:11931757, PubMed:12435635, PubMed:12769844, PubMed:12840033, PubMed:15342634, PubMed:15668399, PubMed:15949444, PubMed:16103164, PubMed:17962192, PubMed:16581786, PubMed:16951159, PubMed:17908926, PubMed:32267835). Degradation of TAL1 also requires STUB1 (PubMed:17962192). Recognizes CDKN1A in association with CCNE1 or CCNE2 and CDK2 (PubMed:16262255). Promotes ubiquitination and destruction of CDH1 in a CK1-dependent manner, thereby regulating cell migration (PubMed:22770219)

The "SKP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SKP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets